10x Genomics announced clinical collaborations with Brigham & Women’s Hospital, Dana‑Farber Cancer Institute and the Cancer Research Institute and committed to build a CLIA‑certified laboratory to enable clinical deployment of single‑cell and spatial assays. The company said it expects the CLIA lab to be ready within about a year. The agreements formalize 10x’s shift from research‑only tools toward clinical evidence generation and diagnostics utility. CEO Serge Saxonov framed the move as a response to physician demand for clinical single‑cell and spatial testing and as a strategic step to expand the company’s addressable market. If adopted broadly, clinical use of single‑cell and spatial technologies could reshape biomarker discovery and personalized oncology workflows, but regulatory, reimbursement and workflow integration challenges remain.